ClinicalTrials.gg
CompletedNCT04014062Updated Oct 4, 2019Results posted

Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

A Phase 1 interventional study of INTP5 and US Neulasta in Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers, sponsored by Intas Pharmaceuticals, Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Intas Pharmaceuticals, Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2018, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study was an assessor-blind, balanced, randomized, two-treatment, two-period, single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD) study of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; INTP5 and US-Neulasta) in healthy, adult, human subjects under fed conditions.

02

Conditions studied

  • Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers

Keywords

  • Pegfilgrastim
  • Biosimilar
  • Bioequivalence
  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • Healthy Volunteers
03

In context

Lead sponsor

Intas Pharmaceuticals, Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Normal, healthy adult human volunteers between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
  2. Having body weight ≥50 kg and (BMI) between 18.5 and 29.9 (both inclusive), calculated as weight in kg/height in meter\^2.
  3. Not having any significant disease in medical history or abnormal findings during screening, abdominal ultrasonography, medical history, clinical examination, laboratory evaluations, 12-lead and chest X-ray (posterior-anterior view; within the last 6 months) recordings.
  4. Volunteer who is a Non-smoker
  5. Able to understand and comply with the study procedures, in the opinion of the investigator.
  6. Able to give voluntary written for participation in the trial.
  7. In case of female subjects:

    • Surgically sterilized at least 6 months prior to study participation;- Or - If a woman of is willing to use a suitable and effective double barrier method or intra uterine device during the study.
    • Serum pregnancy test (for female subjects) must be negative.

Exclusion criteria

Exclusion Criteria:

  1. Known to the study drug or its constituents and/or hypersensitivity to E. coli derived proteins, and/or previous exposure to the study drug.
  2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
  3. Known case of hereditary fructose intolerance.
  4. Subjects with latex allergies will be excluded as the needle cover on the single-use pre-filled syringe contains dry natural rubber (latex).
  5. Any laboratory finding including ANC, , RBC count or level at the time of screening.
  6. Prior exposure to any peptide colony stimulating or growth factor, including erythropoietin, filgrastim or Pegfilgrastim; Prior exposure to vaccines, immunoglobulin preparations, or immunomodulator's within the past 6 months prior to receiving the first dose; evidence of E. coli diarrhea or diseases within 3 months.
  7. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAIDs induced urticaria.
  8. Subjects with a history of pulmonary infiltrate or pneumonia in the last 6 months.
  9. History of any hematologic disease including sickle cell disorders.
  10. Smokers, or who have smoked within last six months prior to start of the study.
  11. Ingestion or use of any prescribed medication at any time within 1 month prior to receiving first dose in Period-I.
  12. Receipt of over-the-counter medicines which have not yet cleared from the body (5 half-lives must have passed for the medicine to be considered to have cleared from the body).
  13. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or alcoholic products within 72 hours prior to receiving study medicine in Period-I.
  14. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
  15. Donation of blood (1 unit or 350 mL) or equivalent amount of blood substitute. Receipt of an medicinal product or participation in a drug research study within a period of 180 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
  16. Positive result for (HIV I \&/or II) and/or and C tests.
  17. History or presence of cancer because of which anticipated life span is less than 5 years as per the investigator's assessment.
  18. History or presence of psychiatric disorders.
  19. Presence of tattoo or scars or any type of skin lesions due to infection, burning, wound or inflammation at the proposed site of injection.
  20. An unusual diet, for whatever reason (e.g. low-sodium), for 4 weeks prior to receiving the study medicine in Period-I. In any such case, subject selection will be at the discretion of the Principal Investigator.
  21. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving study drug in Period-I.
  22. A history of difficulty in donating blood.
  23. Females, pregnant or lactating, or planning to become pregnant during the course of the study or found positive in pregnancy test at screening.
  24. Any infections in the last 4 weeks before receiving study medication in Period-I.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    INTP5 Period I Crossover

    Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL. Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta.

    Combination Product: INTP5 · Combination Product: US Neulasta

  • Active comparator
    US Neulasta Period I Crossover

    Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL. Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5.

    Combination Product: INTP5 · Combination Product: US Neulasta

Interventions

  • Combination productINTP5

    INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.

  • Combination productUS Neulasta

    US Neulasta: FDA-approved pegfilgrastim innovator product.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]

    Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  2. Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]

    Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/λz(lambda-z), Ct is the last measurable concentration and λz(lambda-z) is the terminal rate constant.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  3. Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC

    Maximum measured absolute neutrophil count (ANC).

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  4. Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC

    Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

Secondary outcomes

  1. PK Endpoint: Pegfilgrastim AUC[0-t]

    Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  2. PK Endpoint: Pegfilgrastim T[Max]

    The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  3. PK Endpoint: Pegfilgrastim λz(Lambda-z)

    Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  4. PK Endpoint: Pegfilgrastim R^2 Adjusted

    Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz. R\^2 is the coefficient of Determination and can range from 0 to 1,; with higher values indicating greater predictability.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  5. PK Endpoint: Pegfilgrastim t[1/2]

    The terminal half-life calculated using the formula 0.693/λz(lambda-z).

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  6. PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]

    The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\]0-t\])/AUC0-infinity\] x 100.

    Time frame: Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.

  7. PD Endpoint: T[Max] for Baseline Non-adjusted ANC

    Time to reach the maximum measured absolute neutrophil count (ANC)

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  8. PD Endpoint: E[Max], Baseline-adjusted ANC

    Maximum measured absolute neutrophil count (ANC)

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  9. PD Endpoint: AUEC[0-t], Baseline-adjusted ANC

    Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  10. PD Endpoint: T[Max], Baseline-adjusted ANC

    Time to reach the maximum measured absolute neutrophil count (ANC)

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  11. PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC

    First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated via linear regression of time vs. log concentration. This parameter will be calculated by linear least squares regression analysis using at least last three or more non-zero values.

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

  12. PD Endpoint: t[1/2] for Baseline-adjusted ANC

    The terminal half-life will be calculated as 0.693/λz(lamda-z).

    Time frame: Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.

Other outcomes

  1. Immunogenicity: Presence of Anti-drug Antibodies

    Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.

    Time frame: 0-71 Days

07

Results

Posted Oct 4, 2019

Participant flow

Period I: Dosing
Participant flow — Period I: Dosing
MilestoneINTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II Crossover
Started7171
Completed6465
Not completed76
Withdrew: Medical grounds45
Withdrew: Withdrawal by subject31
Period II: Crossover Dosing
Participant flow — Period II: Crossover Dosing
MilestoneINTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II Crossover
Started6465
Completed6465
Not completed00

Outcome measures

PrimaryPharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]

Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]
ng/mLINTP5 TreatmentUS Neulasta Treatment
Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]474.269 ± 240.2247425.578 ± 219.8054
PrimaryPharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]

Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/λz(lambda-z), Ct is the last measurable concentration and λz(lambda-z) is the terminal rate constant.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · ng.h/mL
Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]
ng.h/mLINTP5 TreatmentUS Neulasta Treatment
Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]21015.8632 ± 12985.376018327.4192 ± 11156.1580
PrimaryPharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC

Maximum measured absolute neutrophil count (ANC).

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · x10^3 cells/uL
Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC
x10^3 cells/uLINTP5 TreatmentUS Neulasta Treatment
Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC38.82 ± 9.00937.97 ± 9.258
PrimaryPharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC

Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · x10^3 cells*h/uL
Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC
x10^3 cells*h/uLINTP5 TreatmentUS Neulasta Treatment
Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC6638.12 ± 1404.3766554.04 ± 1465.072
SecondaryPK Endpoint: Pegfilgrastim AUC[0-t]

Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · ng.h/mL
PK Endpoint: Pegfilgrastim AUC[0-t]
ng.h/mLINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim AUC[0-t]21001.567 ± 12983.981118312.112 ± 11156.5248
SecondaryPK Endpoint: Pegfilgrastim T[Max]

The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · h
PK Endpoint: Pegfilgrastim T[Max]
hINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim T[Max]26.189 ± 6.811025.754 ± 7.6188
SecondaryPK Endpoint: Pegfilgrastim λz(Lambda-z)

Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · 1/h
PK Endpoint: Pegfilgrastim λz(Lambda-z)
1/hINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim λz(Lambda-z)0.021 ± 0.00940.019 ± 0.0088
SecondaryPK Endpoint: Pegfilgrastim R^2 Adjusted

Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz. R\^2 is the coefficient of Determination and can range from 0 to 1,; with higher values indicating greater predictability.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · Coefficient of Determination
PK Endpoint: Pegfilgrastim R^2 Adjusted
Coefficient of DeterminationINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim R^2 Adjusted0.968 ± 0.05430.967 ± 0.0344
SecondaryPK Endpoint: Pegfilgrastim t[1/2]

The terminal half-life calculated using the formula 0.693/λz(lambda-z).

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · h
PK Endpoint: Pegfilgrastim t[1/2]
hINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim t[1/2]39.963 ± 18.554844.824 ± 29.3461
SecondaryPK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]

The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\]0-t\])/AUC0-infinity\] x 100.

Time frame:
Samples withdrawn at 1 hour pre-dose , at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (D-2), 26, 30, 36, 42, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 240 (D-11), 288 (D-13), 336 (D-15) & 504 (D-22) hours post-dose.
Reported as:
Mean · percent of AUC
PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]
percent of AUCINTP5 TreatmentUS Neulasta Treatment
PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]0.105 ± 0.1170.139 ± 0.1726
SecondaryPD Endpoint: T[Max] for Baseline Non-adjusted ANC

Time to reach the maximum measured absolute neutrophil count (ANC)

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · h
PD Endpoint: T[Max] for Baseline Non-adjusted ANC
hINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: T[Max] for Baseline Non-adjusted ANC67.231 ± 16.055363.734 ± 13.1649
SecondaryPD Endpoint: E[Max], Baseline-adjusted ANC

Maximum measured absolute neutrophil count (ANC)

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · x10^3 cells/uL
PD Endpoint: E[Max], Baseline-adjusted ANC
x10^3 cells/uLINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: E[Max], Baseline-adjusted ANC34.66 ± 8.53133.84 ± 8.863
SecondaryPD Endpoint: AUEC[0-t], Baseline-adjusted ANC

Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · x10^3cells*h/uL
PD Endpoint: AUEC[0-t], Baseline-adjusted ANC
x10^3cells*h/uLINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: AUEC[0-t], Baseline-adjusted ANC4626.40 ± 1163.8064565.80 ± 1278.987
SecondaryPD Endpoint: T[Max], Baseline-adjusted ANC

Time to reach the maximum measured absolute neutrophil count (ANC)

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · h
PD Endpoint: T[Max], Baseline-adjusted ANC
hINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: T[Max], Baseline-adjusted ANC67.231 ± 16.055363.734 ± 20.7
SecondaryPD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC

First order rate constant associated with the terminal (log-linear) portion of the curve. This is estimated via linear regression of time vs. log concentration. This parameter will be calculated by linear least squares regression analysis using at least last three or more non-zero values.

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · 1/h
PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC
1/hINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC0.02 ± 0.0110.02 ± 0.013
SecondaryPD Endpoint: t[1/2] for Baseline-adjusted ANC

The terminal half-life will be calculated as 0.693/λz(lamda-z).

Time frame:
Samples were withdrawn 1 hour pre-dose and at 6, 12, 24 (D-2), 36, 48 (D-3), 60, 72 (D-4), 96 (D-5), 120 (D-6), 144 (D-7), 168 (D-8), 192 (D-9), 216 (D-10), 240 (D-11), 288 (D-13), 312 (D-14), 336 (D-15), 360 (D-16) and 504 (D-22) hours post-dose.
Reported as:
Mean · h
PD Endpoint: t[1/2] for Baseline-adjusted ANC
hINTP5 TreatmentUS Neulasta Treatment
PD Endpoint: t[1/2] for Baseline-adjusted ANC55.98 ± 34.97356.27 ± 31.671
Other pre-specifiedImmunogenicity: Presence of Anti-drug Antibodies

Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.

Time frame:
0-71 Days
Reported as:
Count of participants · Participants
Immunogenicity: Presence of Anti-drug Antibodies
ParticipantsINTP5 TreatmentUS Neulasta Treatment
Period I — Negative for anti-drug-32
Period I — Positive for anti-PegG-CSF11
Period I — Not Tested for Immunogenicity6062
Period I — Neutralizing antibody00
Period II — Negative for anti-drug-00
Period II — Positive for anti-PegG-CSF00
Period II — Not Tested for Immunogenicity6465
Period II — Neutralizing antibody00

Adverse events

Collected over 79 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INTP5 Treatment0/136 (0%)0/136 (0%)39/136 (28.7%)
US Neulasta Treatment0/135 (0%)0/135 (0%)39/135 (28.9%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventINTP5 TreatmentUS Neulasta Treatment
Musculoskeletal painMusculoskeletal and connective tissue disorders16/13619/135
HeadacheNervous system disorders12/13612/135
Injection site painGeneral disorders2/1365/135
VomitingGastrointestinal disorders4/1362/135
PyrexiaGeneral disorders1/1363/135
Human chorionic gonadotropin increasedInvestigations2/1363/135
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1361/135
Lacrimation increasedEye disorders0/1361/135
Abdominal painGastrointestinal disorders0/1361/135
DiarrhoeaGastrointestinal disorders0/1361/135

Baseline characteristics

Age, Continuous
Age, Continuous(years)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
Mean34.7 ± 5.7432.5 ± 6.3833.6 ± 6.15
Sex: Female, Male
Sex: Female, Male(Participants)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
Female363672
Male353570
Race (NIH/OMB)
Race (NIH/OMB)(Participants)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
American Indian or Alaska Native000
Asian7171142
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
India7171142
Height
Height(cm)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
Mean159.1 ± 7.99159.3 ± 9.00159.2 ± 8.48
Weight
Weight(kg)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
Mean60 ± 7.4261.6 ± 8.4960.8 ± 7.98
BMI
BMI(kg/m^2)INTP5 Period I, US Neulasta Period II CrossoverUS Neulasta Period I, INTP5 Period II CrossoverTotal
Mean23.77 ± 2.78824.32 ± 3.18824.04 ± 2.996
08

Study locations

1 site
  • Lambda Therapeutic Research Ltd.
    Ahmedabad, Gota Ahmedabad-382481, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in May 2018, 2 months.

Results were first posted in Oct 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 10, 2019
StartActual
Feb 12, 2018
Primary completionActual
May 1, 2018
CompletionActual
May 1, 2018
Results first posted
Oct 4, 2019
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04014062
Lead sponsor
Intas Pharmaceuticals, Ltd.
Collaborators
Lambda Therapeutic Research Ltd.
Responsible party
Sponsor
First posted
Jul 10, 2019
Start date
Feb 12, 2018
Primary completion
May 1, 2018
Completion
May 1, 2018
Results posted
Oct 4, 2019
Last update
Oct 4, 2019

Study contacts

Anshul Attrey, M.D.
principal investigator · Lambda Therapeutic Research Ltd.
Vinu Jose, M.D.
study director · Intas Pharmaceuticals, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion